The DOI matches its Crossref record.
Association of C‐erb B‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer
Abstract
C‐erb B‐2 protein over‐expression was studied immunohis‐tochemically in 319 paraffin‐embedded breast carcinomas representing 89% of all breast‐cancer cases operated in the Tampere University Hospital between 1977 and 1981. The immunohistochemical evaluation of c‐erb B‐2 was optimized using protease pre‐treatment and verified using antibodies for both the external and the internal domains of the protein. c‐erb B‐2 over‐expression was found in 72 (23%) of the 319 cases and was associated with high histological and nuclear grade (p< 0.0001), DNA aneuploidy (p= 0.003), high tumor S‐phase fraction (p< 0.000l), and lack of estrogen (p< 0.0001) and progesterone (p= 0.03) receptors. Overall, breast‐cancer patients with c‐erb B‐2 over‐expression had about 2.2‐fold relative risk (RR) of death (p< 0.001) as compared with those without over‐expression. According to a multivariate analysis, c‐erb B‐2 over‐expression was an independent prognostic factor in the whole material as well as in the node‐negative sub‐set. In node‐negative breast‐cancer tumor size, S‐phase and c‐erb B‐2 status defined a large patient group with only 4% 5‐year and 15% 10‐year mortality rate without adjuvant therapy. In comparison with c‐erb B‐2‐negative tumors, those with over‐expression of this gene metastasized 3 times more often (p= 0.0002) to the lungs, liver and brain and 3 times less often to the bone. Our findings suggest that the prognostic value of c‐erb B‐2 over‐expression may be related not only to increased cell proliferation rate but also to a distinctive pattern of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Owens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Metadata
- Authors
- Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., & Isola, J. J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1991-11-11
- Volume
- 49
- Issue
- 5
- Pages
- 650-655
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2061563172
- Cited by
- 346
- References
- 0
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of C‐erb B‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer. https://app.cochat.ai/papers/10.1002/ijc.2910490504
- The paper
- Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., & Isola, J. J. (1991). Association of C‐erb B‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.2910490504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.